Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10640 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3F10 | |
| SCHEMBL5786234 | 0.82 | SIGMAR1 (0.43) | SLC6A2SLC6A4SLC6A3F10SIGMAR1 | |
| SCHEMBL8352677 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3F10F2 | |
| SCHEMBL5827078 | 0.81 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3F10F2 | |
| Ammonia Solution, Strong SCHEMBL5827077 | 0.80 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3F10F2 | |
| SCHEMBL8353033 | 0.76 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3F10F2 | |
| SCHEMBL8351046 | 0.76 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5642929 | 0.76 | F10 (0.49) | SLC6A2SLC6A4SLC6A3F10F2 | |
| SCHEMBL6896148 | 0.75 | SLC6A4 (0.69) | SLC6A2SLC6A4SLC6A3F10OPRM1 | |
| SCHEMBL16521003 | 0.75 | SLC6A4 (0.65) | SLC6A2SLC6A4SLC6A3F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | SLC6A2 2844/4885SLC6A4 2705/4885SLC6A3 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.